Analyst firms · Wolfe Research · ALNY
Wolfe Research ALNY price target and rating history
Alnylam Pharmaceuticals Inc. (ALNY) · Health Care
Wolfe Research rates Alnylam Pharmaceuticals Inc. (ALNY) Peer Perform, as of its latest action on Aug 4, 2025. It has published 3 rating actions on ALNY since February 2024, including 1 upgrade and 1 downgrade. Across 10 firms with a ALNY price target in the last 12 months, the median target is $324.
- Current rating
- Peer Perform
- Price target
- Not stated
- Median target, all firms
- $324
- Actions on ALNY
- 3
Every Wolfe Research rating on ALNY
- Aug 4, 2025
- Nov 12, 2024
- Feb 15, 2024
How other firms rate ALNY
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Truist Securities | Hold | $225 | Nov 2, 2026 |
| Bernstein | Mkt Perform | $199 | Oct 30, 2026 |
| Raymond James | Outperform | $315 | Oct 30, 2026 |
| Stifel | Hold | $225 | Oct 29, 2026 |
| UBS | Buy | $354 | Oct 15, 2026 |
| BMO Capital Markets | Outperform | $318 | Aug 19, 2026 |
| Citigroup | Buy | $380 | May 19, 2026 |
| Jefferies | Hold | $330 | Mar 16, 2026 |
| Barclays | Overweight | $527 | Jan 28, 2026 |
| Oppenheimer | Outperform | $500 | Jan 7, 2026 |
Questions about Wolfe Research and ALNY
- What is Wolfe Research's rating on ALNY?
- Wolfe Research rates ALNY Peer Perform, a neutral rating, as of Aug 4, 2025.
- When did Wolfe Research last change its view on ALNY?
- On Aug 4, 2025, Wolfe Research upgrades to Peer Perform from Underperform.
- How does Wolfe Research's ALNY target compare with other analysts?
- Across 10 firms with a ALNY price target in the last 12 months, the median target is $324.
More ALNY rating histories
- Raymond James4
- BMO Capital Markets3
- Oppenheimer4
- Goldman Sachs3
- Morgan Stanley8
- Leerink Partners3
- Piper Sandler3
All Wolfe Research ratingsALNY news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.